Louie Pasculli

In a pilot study, liraglutide, a drug used for diabetes and weight-loss, significantly reduced headache days in patients with obesity and chronic or high-frequency migraine, suggesting a potential new preventive therapy.

The director of the EEG/Epilepsy Unit in the Department of Clinical Neurosciences at Lausanne University Hospital in Switzerland discussed post-anoxic seizure management at 2025 AES Annual Meeting. [WATCH TIME: 3 minutes]

Follow NeurologyLive's conference journey in 2026, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

The Baldwin Keyes Professor of Neurology at the Sidney Kimmel Medical College at Thomas Jefferson University and Founder’s Award recipient discussed the state of the epilepsy care community and his outlook for the future. [WATCH TIME: 4 minutes]

A new large-scale analysis revealed that patients with identical EDSS scores can exhibit distinct patterns of functional impairment, identified using artificial intelligence–based clustering algorithms.

Benjamin Greenberg, MD, MHS, a nationally recognized neuroimmunologist, spoke about the clinical impact of the latest NMOSD recommendations and their implications for diagnosis and care.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on preventative migraine therapies!

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on RBD as a prodromal marker for synucleinopathies!

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neuromodulation for Parkinson disease!

A neuroscientist associated with the Cleveland Clinic Epilepsy Center discussed the rapid expansion and excitement surrounding the continued integration of AI in the field of epilepsy care. [WATCH TIME: 5 minutes]

Andy Berkowski, MD, PhD, certified sleep neurologist and author of the RLS guidelines, spoke about the clinical impact of the recently published restless syndrome guidelines.

At AES 2025, a clinical neuropsychologist at the Cleveland Clinic Epilepsy Center discussed the growing challenges facing older adults with epilepsy and the need for more comprehensive, research-informed care strategies. [WATCH TIME: 4 minutes]

Andrea Rossetti, MD, director of the EEG/Epilepsy Unit at the Department of Clinical Neurosciences the Lausanne University Hospital in Switzerland, offers insight into post-resuscitation epilepsy care.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on FcRn-blocking therapies in neurology!

Michael Sperling, MD, Baldwin Keyes Professor of Neurology at Vice Chair for Research at the Sidney Kimmel Medical College, spoke about the significance of receiving the Founders Award and the current state of epilepsy.

New data from the open-label extension of Harmony Biosciences’ Phase 3 ARGUS trial show that EPX-100 (clemizole) achieved a median 50% reduction in countable motor seizures in patients with Dravet Syndrome.

A recent survey reveals fever significantly reduces seizure frequency in CDKL5 Deficiency Disorder, highlighting potential therapeutic strategies for patients.

The clinician educator at the University of Toronto discussed the complex challenge of caring for women with epilepsy that demands both clinical expertise and personalized care. [WATCH TIME: 4 Minutes]

A new phase 2 study presented at AES 2025 showed that stiripentol may reduce seizure burden in patients with Lennox-Gastaut syndrome.

Findings from a phase 2 trial highlighted lacosamide's effectiveness and safety in treating neonatal seizures, showing significant seizure reduction and tolerability in patients.

New data highlights cenobamate's effectiveness in reducing focal seizures in Asian populations, showcasing significant improvements and potential long-term benefits for patients.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on autonomic dysfunction in long COVID!

Merck's MK-2214 shows promise in early Alzheimer’s trials, earning FDA fast-track status for its safety and potential efficacy in slowing disease progression.

The POLARIS-AD phase 3 large-scale global trial is now underway, testing the safety and efficacy of AR1001 in over 1500 patients with mild cognitive impairment or early Alzheimer disease.

The adaptive PRImus-AD phase 2a trial will evaluate the safety and efficacy of PRI-002, a novel investigational agent, in patients with mild cognitive impairment or mild Alzheimer disease.

A new phase 3 clinical trial is underway to evaluate masupirdine, a selective 5-HT6 receptor antagonist, as a potential treatment for agitation in patients with Alzheimer’s disease.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Phosphorylated tau 181!

The medical director of the stroke recovery program at JFK Johnson Rehabilitation Institute at Hackensack Meridian Health discussed the role health insurance plays in stroke survivors receiving rehabilitation care. [WATCH TIME: 4 minutes]

Enna Selmanovic, a PhD candidate at Mount Sinai, spoke on a recently published study regarding the incidence of traumatic brain injury and the potential for long-term health issues with chronic traumatic encephalopathy.

Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.